Section Arrow
Quote
BMRN.NASDAQ
- BioMarin Pharmaceutical
Quotes are at least 15-min delayed:2025/07/16 16:25 EDT
After Hours
Last
 58.39
0 (0.00%)
Bid
57.3
Ask
60.22
High 59.2 
Low 58.39 
Volume 28933 
Regular Hours
Last
 58.39
+1.77 (+3.13%)
Day High 
58.58 
Prev. Close
56.62 
1-M High
59.98 
Volume 
1.66M 
Bid
57.3
Ask
60.22
Day Low
56.82 
Open
56.94 
1-M Low
53.715 
Market Cap 
10.86B 
Currency USD 
P/E 20.97 
%Yield -- 
10-SMA 57.77 
20-SMA 56.32 
50-SMA 57.57 
52-W High 94.85 
52-W Low 52.93 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.70/5.13
Enterprise Value
11.45B
Balance Sheet
Book Value Per Share
30.21
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
2.85B
Operating Revenue Per Share
12.05
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
APMAptorum Group Limited1.94+0.9702+100.04%2.77PE
After Hours 2.0297 +0.0897 +4.62%
TNFATNF Pharmaceuticals Inc.0.109+0.0028+2.64%-- 
After Hours 0.1034 -0.0056 -5.14%
NCNANuCana plc0.0502--0.000%-- 
After Hours 0.0503 +0.0001 +0.20%
BRNSBarinthus Biotherapeutics plc1.42+0.4+39.22%-- 
After Hours 1.3399 -0.0801 -5.64%
WINTWindtree Therapeutics Inc.0.9+0.0714+8.62%0.84PE
After Hours 0.8592 -0.0408 -4.53%
Quotes are at least 15-min delayed：2025/07/16 16:25 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline oftreatments in development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.